A new generation of antiplatelet agents

Current Opinion in Cardiology

Volumn 24, Issue 4, 2009, Pages 307-312

  Sellers, Matthew B ^a,b   Tricoci, Pierluigi ^a,b   Harrington, Robert A ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndromes; Acute myocardial infarction; Antiplatelet agents; Aspirin; Clopidogrel; Thienopyridines; Von Willebrand factor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTITHROMBOCYTIC AGENT; ARC 1779; CANGRELOR; CLOPIDOGREL; PLACEBO; PRASUGREL; SCH 530348; TICAGRELOR; UNCLASSIFIED DRUG; P2RY12 PROTEIN, HUMAN; PURINERGIC P2 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; PYRIDINE DERIVATIVE; THIENOPYRIDINE DERIVATIVE; THROMBIN RECEPTOR; TICLOPIDINE; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERSENSITIVITY REACTION; LOADING DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOSIS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; ASPIRIN; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTORS, PURINERGIC P2; RECEPTORS, PURINERGIC P2Y12; RECEPTORS, THROMBIN; TICLOPIDINE; VON WILLEBRAND FACTOR;

EID: 67651152741     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32832e2b44     Document Type: Review

References (31)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360.
2. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1607-1621. (Pubitemid 41552416)
3. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352:1179-1189. (Pubitemid 40397259)
4. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502. (Pubitemid 32758501)
5. Mehta SR, Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003; 41:79S-88S. (Pubitemid 36223351)
6. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411-2420.
7. Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J 2008; 156:S10-S15. (Pubitemid 352020407)
8. Nurden AT, Nurden P. Advantages of fast-acting ADP receptor blockade in ischemic heart disease. Arterioscler Thromb Vasc Biol 2003; 23:158-159. (Pubitemid 36231922)
9. O'Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies: clopidogrel: does one size fit all? Circulation 2006; 114:e600-e606.
10. Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fastmoving story. Circulation 2004; 109:3064-3067.
11. Badimon L, Vilahur G. Coronary atherothrombotic disease: progress in antiplatelet therapy. Rev Esp Cardiol 2008; 61:501-513. (Pubitemid 351930602)
12. Nimjee SM, Rusconi CP, Harrington RA, Sullenger BA. The potential of aptamers as anticoagulants. Trends Cardiovasc Med 2005; 15:41-45.
13. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116:2678-2686. (Pubitemid 350291240)
14. Angiolillo DJ, Bates ER, Bass TA. Clinical profile of prasugrel, a novel thienopyridine. Am Heart J 2008; 156:S16-S22.
15. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111:3366-3373.
16. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116:2923-2932. (Pubitemid 350291199)
17. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015. (Pubitemid 350106708)
18. Jacobsson F, Swahn E, Wallentin L, Ellborg M. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin Ther 2002; 24:752-765. (Pubitemid 34596944)
19. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and ARC69931MX in patients with ischaemic heart disease. Platelets 2002; 13:407-413. (Pubitemid 35346941)
20. Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y 12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006; 151:689.e1-689.e10.
21. Storey RF, Oldroyd KG,Wilcox RG.Open multicentre study of theP2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001; 85:401-407.
22. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27:1038-1047.
23. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50:1844-1851. (Pubitemid 350007959)
24. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50:1852-1856. (Pubitemid 350017792)
25. Ray KK, Morrow DA, Gibson CM, et al. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 substudy. Eur Heart J 2005; 26:440-446.
26. Angiolillo DJ, Guzman LA. Clinical overview of promising nonthienopyridine antiplatelet agents. Am Heart J 2008; 156:S23-S28.
27. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing nonurgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373:919-928. A randomized clinical trial assessing the novel thrombin receptor antagonist in patients undergoing PCI. The trial suggested the possibility that the drug may reduce ischemic complications without increasing the rate of bleeding.
28. Gresele P, Momi S. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc Drug Rev 2006; 24:148-168. (Pubitemid 46696922)
29. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343:834-839.
30. Fiorucci S, Santucci L, Gresele P, et al. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003; 124:600-607. (Pubitemid 36268478)
31. Fiorucci S, Santucci L, Wallace JL, et al. Interaction of a selective cyclooxygenase- 2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci U S A 2003; 100:10937-10941. (Pubitemid 37140131)